<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.0 20040830//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">09-PONE-RA-11909R1</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0007857</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Immunology/Autoimmunity</subject><subject>Diabetes and Endocrinology/Endocrinology</subject><subject>Diabetes and Endocrinology/Thyroid</subject><subject>Pathology/Cellular Pathology</subject><subject>Pathology/Histopathology</subject><subject>Pathology/Immunology</subject><subject>Pathology/Molecular Pathology</subject></subj-group></article-categories><title-group><article-title>Immunoproteasome Overexpression Underlies the Pathogenesis of Thyroid Oncocytes and Primary Hypothyroidism: Studies in Humans and Mice</article-title><alt-title alt-title-type="running-head">LMP2 Regulates Thyroid Disease</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kimura</surname><given-names>Hiroaki J.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Cindy Y.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tzou</surname><given-names>Shey-Cherng</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Rocchi</surname><given-names>Roberto</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Landek-Salgado</surname><given-names>Melissa A.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Suzuki</surname><given-names>Koichi</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kimura</surname><given-names>Miho</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Rose</surname><given-names>Noel R.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Caturegli</surname><given-names>Patrizio</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Department of Pathology, The Johns Hopkins School of Medicine, Baltimore, Maryland, United States of America</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Department of Bioregulation, Leprosy Research Center, National Institute of Infectious Diseases, Tokyo, Japan</addr-line></aff><aff id="aff3"><label>3</label><addr-line>Feinstone Department of Molecular Microbiology and Immunology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>R&#x000e9;nia</surname><given-names>Laurent</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">BMSI-A&#x0002a;STAR, Singapore</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>pcat@jhmi.edu</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: HJK NRR PC. Performed the experiments: HJK CYC SCT RR MALS KS MK. Analyzed the data: HJK PC. Contributed reagents/materials/analysis tools: HJK CYC SCT RR MALS KS MK PC. Wrote the paper: HJK PC.</p></fn></author-notes><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>17</day><month>11</month><year>2009</year></pub-date><volume>4</volume><issue>11</issue><elocation-id>e7857</elocation-id><history><date date-type="received"><day>27</day><month>7</month><year>2009</year></date><date date-type="accepted"><day>14</day><month>10</month><year>2009</year></date></history><permissions><copyright-statement>Kimura et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement></permissions><abstract><sec><title>Background</title><p>Oncocytes of the thyroid gland (H&#x000fc;rthle cells) are found in tumors and autoimmune diseases. They have a unique appearance characterized by abundant granular eosinophilic cytoplasm and hyperchromatic nucleus. Their pathogenesis has remained, thus far, unknown.</p></sec><sec><title>Methodology/Principal Findings</title><p>Using transgenic mice chronically expressing IFN&#x003b3; in thyroid gland, we showed changes in the thyroid follicular epithelium reminiscent of the human oncocyte. Transcriptome analysis comparing transgenic to wild type thyrocytes revealed increased levels of immunoproteasome subunits like LMP2 in transgenics, suggesting an important role of the immunoproteasome in oncocyte pathogenesis. Pharmacologic blockade of the proteasome, in fact, ameliorated the oncocytic phenotype. Genetic deletion of LMP2 subunit prevented the development of the oncocytic phenotype and primary hypothyroidism. LMP2 was also found expressed in oncocytes from patients with Hashimoto thyroiditis and H&#x000fc;rthle cell tumors.</p></sec><sec><title>Conclusions/Significance</title><p>In summary, we report that oncocytes are the result of an increased immunoproteasome expression secondary to a chronic inflammatory milieu, and suggest LMP2 as a novel therapeutic target for the treatment of oncocytic lesions and autoimmune hypothyroidism.</p></sec></abstract><counts><page-count count="11"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Oncocytes and lymphocytic infiltration are the pathologic hallmarks of Hashimoto thyroiditis, one of the most prevalent autoimmune diseases <xref ref-type="bibr" rid="pone.0007857-Cooper1">&#x0005b;1&#x0005d;</xref>. Thyroid oncocytes, also known as H&#x000fc;rthle cells, Askanazy cells, or oxyphilic cells, derive from the thyroid follicular cell and are characterized by an abundant, eosinophilic and granular cytoplasm (the consequence of an increased number of mitochondria) and a large, hyperchromatic nucleus with prominent nucleoli <xref ref-type="bibr" rid="pone.0007857-Caturegli1">&#x0005b;2&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007857-Tallini1">&#x0005b;3&#x0005d;</xref>. Thyroid oncocytes are found not only in Hashimoto thyroiditis but also in long-standing Graves disease, multinodular goiter, benign thyroid neoplasms (H&#x000fc;rthle cell adenoma and granular cell tumor), and malignant thyroid neoplasms (H&#x000fc;rthle cell carcinoma, oncocytic variant of papillary carcinoma, Warthin-like variant of papillary carcinoma, and tall cell variant of papillary carcinoma) <xref ref-type="bibr" rid="pone.0007857-Montone1">&#x0005b;4&#x0005d;</xref>. Oncocytes, however, are not limited to the thyroid gland. They are also found in other organs like kidneys and salivary glands.</p><p>The pathogenesis of oncocytes has remained overall unknown. We have previously developed a mouse model of Hashimoto thyroiditis based on the chronic production of interferon-gamma (IFN&#x003b3;) by the thyroid follicular cell via transgenesis <xref ref-type="bibr" rid="pone.0007857-Caturegli2">&#x0005b;5&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007857-Kimura1">&#x0005b;6&#x0005d;</xref>. These mice develop primary hypothyroidism as the direct consequence of a chronic, cytokine-mediated, inhibition of thyroid function, a phenotype that is present also in the absence of infiltrating lymphocytes (obtained by crossing the transgenic mice to RAG deficient mice) <xref ref-type="bibr" rid="pone.0007857-Caturegli2">&#x0005b;5&#x0005d;</xref>. Interestingly, the thyrocytes of IFN&#x003b3; transgenic mice assume a morphology resembling that of the human oncocyte.</p><p>This paper highlights the role of the immunoproteasome in the pathogenesis of thyroid oncocytes and hypothyroidism. The proteasome is a large barrel-shaped, proteolytic complex present in the nucleus and cytoplasm of all cells to degrade proteins marked with ubiquitin <xref ref-type="bibr" rid="pone.0007857-Tanaka1">&#x0005b;7&#x0005d;</xref>. It is implicated in a number of fundamental cellular activities such as the processing of antigens presented by MHC class I molecules <xref ref-type="bibr" rid="pone.0007857-Kloetzel1">&#x0005b;8&#x0005d;</xref>. The constitutive proteasome is made of a 20S catalytic core closed at both ends by a 19S cap. The core is formed by four stacked rings, each made of seven subunits: two alpha rings are on the sides and allow the entrance of only denatured proteins; two beta rings are in the center and perform the protease activity, reducing proteins to small peptides of 3&#x02013;23 amino acids. Proteolysis is carried out by three beta subunits, &#x003b2;1, &#x003b2;2, and &#x003b2;5, which harbor postglutamyl peptide hydrolytic-like, trypsin-like, and chymotrypsin-like activities, respectively. When the cell is stimulated by IFN&#x003b3; or other inflammatory stimulants like tumor necrosis factor &#x003b1;, three subunits in the beta rings and two in the cap are replaced by new subunits called i&#x003b2;1 (or LMP2), i&#x003b2;2 (or LMP10), i&#x003b2;5 (or LMP7), PA28&#x003b1; and PA28&#x003b2;, overall giving to the complex the name of &#x0201c;immunoproteasome&#x0201d;. The i&#x003b2;1 and i&#x003b2;2 subunits must be assembled together, and similarly PA28&#x003b1; and PA28&#x003b2;, but variations in immunoproteasome do exist. The genes coding for LMP subunits are embedded within the class II region of the MHC locus on chromosome 6, and are therefore in strong linkage disequilibrium with the classical MHC class II molecules (DP, DR, DQ) that have been associated with numerous autoimmune diseases. In this paper we show that LMP2 is required for the pathogenesis of thyroid oncocytes and hypothyroidism.</p></sec><sec id="s2"><title>Results</title><sec id="s2a"><title>Expression of IFN&#x003b3; in the Thyroid Transforms Normal Thyrocytes into Oncocytes</title><p>The thyrocytes of <italic>thyr</italic>-IFN&#x003b3; transgenic mice crowded along a scanty colloidal space (<xref ref-type="fig" rid="pone-0007857-g001">Figure 1A</xref>, middle panel), assuming a tall and polygonal shape (<xref ref-type="fig" rid="pone-0007857-g001">Figure 1A</xref>, middle panel inset). Their cytoplasm was granular and more eosinophilic than that of wild type thyrocytes (<xref ref-type="fig" rid="pone-0007857-g001">Figure 1A, left panel</xref>), and the nucleus enlarged with a prominent nucleolus, resembling the appearance of the oncocytes (H&#x000fc;rthle cells) found in patients with Hashimoto thyroiditis (<xref ref-type="fig" rid="pone-0007857-g001">Figure 1A, right panel</xref>). These cellular features were confirmed by electron microscopy, which also revealed an increased number and size of mitochondria in transgenic thyrocytes (<xref ref-type="fig" rid="pone-0007857-g001">Figure 1B</xref>). Apoptosis of thyrocytes was not detected by TUNEL in <italic>thyr</italic>-IFN&#x003b3; transgenic mice (<xref ref-type="fig" rid="pone-0007857-g001">Figure 1C</xref>).</p><fig id="pone-0007857-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0007857.g001</object-id><label>Figure 1</label><caption><title>Thyroid histopathology.</title><p>(A) Thyroids from <italic>thyr</italic>-IFN&#x003b3; transgenic mice (middle panel) show a disrupted architecture, with scanty colloid and thickened thyrocytes (inset), an appearance markedly different from that of wild type thyroids (left panel). Thyrocytes from <italic>thyr</italic>-IFN&#x003b3; transgenic mice resemble human H&#x000fc;rthle cells, with eosinophilic and granular cytoplasm and hyperchromatic nucleus, mimicking the features of H&#x000fc;rthle cells from a patient with Hashimoto thyroiditis (right panel). (B) By electron microscopy, <italic>thyr</italic>-IFN&#x003b3; transgenic thyrocytes appear taller (upper right panel) than wild type thyrocytes (upper left panel), and contain more mitochondria (lower right panel, arrow) than wild type (lower left panel). (C) No apoptosis was detected by TUNEL staining in <italic>thyr</italic>-IFN&#x003b3; transgenic thyrocytes.</p></caption><graphic xlink:href="pone.0007857.g001"/></fig></sec><sec id="s2b"><title>Immunoproteasome Subunits Are Highly Expressed in Oncocyte-Like IFN&#x003b3; Transgenic Thyrocytes</title><p>To characterize at the molecular level the pathologic changes seen in <italic>thyr</italic>-IFN&#x003b3; transgenic thyrocytes, we used long serial analysis of gene expression (Long SAGE) and compared gene expression in transgenic and wild type isolated thyrocytes. A total of 43,718 and 43,908 tags were collected from the transgenic and wild type thyroid libraries, respectively. Major histocompatibility complex (MHC) genes were the most highly expressed genes in transgenic thyrocytes (rank 1, 5, 8 and 10 in <xref ref-type="supplementary-material" rid="pone.0007857.s005">Table S1</xref> and 1, 2 and 3 in <xref ref-type="supplementary-material" rid="pone.0007857.s006">Table S2</xref>), whereas thyroglobulin dominated in wild type controls (rank 1, 2, 6, 7, and 9 in <xref ref-type="supplementary-material" rid="pone.0007857.s007">Table S3</xref> and 1, 2, 5 and 7 in <xref ref-type="supplementary-material" rid="pone.0007857.s008">Table S4</xref>). Comparison of expression tags between <italic>thyr</italic>-IFN&#x003b3; transgenic and wild type thyrocytes (<xref ref-type="table" rid="pone-0007857-t001">Table 1</xref>) revealed that, following the MHC genes, immunoproteasome subunits were most abundantly expressed in transgenics. In particular, the beta subunit type 8 (also known as LMP7) was increased 36 fold (<xref ref-type="table" rid="pone-0007857-t001">Table 1</xref>); then, the remaining four immunoproteasome subunits were increased as follows: 14 fold for PA28&#x003b2;, 10 fold for beta subunit type 9 (LMP2), 6 fold for PA28&#x003b1;, and 5 fold for beta subunit type 10 (LMP10) (<xref ref-type="fig" rid="pone-0007857-g002">Figure 2A</xref>). The complete list of expressed tags in the two thyroid libraries can be downloaded from the GEO website (see <xref ref-type="sec" rid="s4">Material and methods</xref>).</p><fig id="pone-0007857-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0007857.g002</object-id><label>Figure 2</label><caption><title>Thyroid expression of immunoproteasome subunits.</title><p>(A) Immunoproteasome SAGE tag numbers, comparing thyr-IFN&#x003b3; transgenic to wild type thyrocytes. (B) Immunoproteasome mRNA levels by semi-quantitative RT-PCR, comparing thyr-IFN&#x003b3; transgenic to wild type thyrocytes. G3PDH is used as housekeeping control. (C) Immunoproteasome protein expression by immunohistochemistry: all subunits are increased in thyr-IFN&#x003b3; transgenic thyroids when compared to wild type thyroids (inset).</p></caption><graphic xlink:href="pone.0007857.g002"/></fig><table-wrap id="pone-0007857-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0007857.t001</object-id><label>Table 1</label><caption><title>Comparison of gene expression by SAGE in thyrocytes isolated from <italic>thyr</italic>-IFN&#x003b3; transgenic (TG) or wild type (WT) mice (shows the genes that displayed the highest TG over WT ratio).</title></caption><alternatives><graphic id="pone-0007857-t001-1" xlink:href="pone.0007857.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Rank</td><td align="left" rowspan="1" colspan="1">Gene Description</td><td align="left" rowspan="1" colspan="1">Unigene ID</td><td align="left" rowspan="1" colspan="1">Fold change (TG over WT)</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">H2-K1 MHC class I heavy chain precursor (H-2K(d))</td><td align="left" rowspan="1" colspan="1">Mm.16771</td><td align="left" rowspan="1" colspan="1">325</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">MHC class I (B7.2) cell surface antigen mRNA, 3&#x02032; end</td><td align="left" rowspan="1" colspan="1">Mm.380380</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">Ecotropic viral integration site 2a</td><td align="left" rowspan="1" colspan="1">Mm.164948</td><td align="left" rowspan="1" colspan="1">182</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Ia-associated invariant chain</td><td align="left" rowspan="1" colspan="1">Mm.276499</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">SH2 domain containing 4A</td><td align="left" rowspan="1" colspan="1">Mm.40974</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">Histocompatibility 2, Q region locus 8 (H2-Q8), mRNA</td><td align="left" rowspan="1" colspan="1">Mm.296901</td><td align="left" rowspan="1" colspan="1">72</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Transcribed locus</td><td align="left" rowspan="1" colspan="1">Mm.34421</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">Connective tissue growth factor</td><td align="left" rowspan="1" colspan="1">Mm.1810</td><td align="left" rowspan="1" colspan="1">51</td></tr><tr><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">Histocompatibility 2, class II antigen E beta (H2-Eb1)</td><td align="left" rowspan="1" colspan="1">Mm.22564</td><td align="left" rowspan="1" colspan="1">38</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">C76746 Adult male epididymis cDNA, RIKEN full-length enriched library, clone:9230104M02 product</td><td align="left" rowspan="1" colspan="1">Mm.358798</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">Proteasome (prosome, macropain) subunit, beta type 8 (large multifunctional peptidase 7: LMP7)</td><td align="left" rowspan="1" colspan="1">Mm.180191</td><td align="left" rowspan="1" colspan="1">36</td></tr><tr><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">Integral membrane protein 2B</td><td align="left" rowspan="1" colspan="1">Mm.4266</td><td align="left" rowspan="1" colspan="1">32</td></tr><tr><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">Ribosomal protein L36</td><td align="left" rowspan="1" colspan="1">Mm.11376</td><td align="left" rowspan="1" colspan="1">21</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Transcribed locus, strongly similar to NP_071949.1 ribosomal protein L36 &#x0005b;Rattus norvegicus&#x0005d;</td><td align="left" rowspan="1" colspan="1">Mm.296314</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rpl36 Adult male heart cDNA, 60S RIBOSOMAL PROTEIN L36 homolog</td><td align="left" rowspan="1" colspan="1">Mm.371604</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rpl36 Sulfatase modifying factor 1 (Sumf1)</td><td align="left" rowspan="1" colspan="1">Mm.379094</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">Transcribed locus</td><td align="left" rowspan="1" colspan="1">Mm.234875</td><td align="left" rowspan="1" colspan="1">20</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">RIKEN cDNA 0610037M15 gene</td><td align="left" rowspan="1" colspan="1">Mm.221293</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Histocompatibility 2, Q region locus 8 (H2-Q8)</td><td align="left" rowspan="1" colspan="1">Mm.296901</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Histocompatibility 2, Q region locus 1</td><td align="left" rowspan="1" colspan="1">Mm.327075</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">Hydroxysteroid (17-beta) dehydrogenase 4</td><td align="left" rowspan="1" colspan="1">Mm.277857</td><td align="left" rowspan="1" colspan="1">19</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CD63 antigen</td><td align="left" rowspan="1" colspan="1">Mm.371552</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives></table-wrap><p>Long SAGE results were confirmed by reverse transcriptase PCR and immunohistochemistry. The mRNA levels of all five immunoproteasome subunits were significantly over-represented in IFN&#x003b3; transgenic compared to wild type thyrocytes (<xref ref-type="fig" rid="pone-0007857-g002">Figure 2B</xref>). Similarly, the protein levels of LMP2, LMP7, LMP10, PA28&#x003b1; and PA28&#x003b2; were more abundant in IFN&#x003b3; transgenics than in controls (<xref ref-type="fig" rid="pone-0007857-g002">Figure 2C</xref>). The increased expression of immunoproteasome subunits was directly dependent upon IFN&#x003b3; signaling because it disappeared when <italic>thyr-</italic>IFN&#x003b3; transgenic mice were crossed to mice lacking Stat1 (<xref ref-type="supplementary-material" rid="pone.0007857.s001">Figure S1A</xref>) and could be reproduced in cultured Fisher rat thyroid cells exposed to IFN&#x003b3; (<xref ref-type="supplementary-material" rid="pone.0007857.s001">Figure S1B</xref>). Based on these findings we hypothesize that the oncocytic phenotype is a consequence of increased immunoproteasome expression, secondary to chronic IFN&#x003b3; stimulation in our system.</p></sec><sec id="s2c"><title>Pharmacologic Inhibition of the Proteasome Ameliorates the Oncocytic Phenotype</title><p>To assess pharmacologically whether proteasome inhibition influenced the thyroid disease typical of <italic>thyr</italic>-IFN&#x003b3; transgenic mice, we used MLN-273, a compound manufactured by Millennium Pharmaceuticals, Inc. (Cambridge, MA) similar to Velcade, with a inhibitory activity against purified proteasome of 0.2 nM <xref ref-type="bibr" rid="pone.0007857-Adams1">&#x0005b;9&#x0005d;</xref>. Mice (N&#x0200a;&#x0003d;&#x0200a;114&#x02236;58 wild type and 56 transgenics) were first treated with increasing doses of formulated MLN-273 (0, 0.1, 0.2, 0.3, 0.4, and 0.5 mg per Kg of mouse weight), following an administration cycle of two injections per week for two weeks and one week of rest (<xref ref-type="fig" rid="pone-0007857-g003">Figure 3A</xref>). Injections were begun during the first week of life (typically on day 3), and ranged from a minimum of 4 to a maximum of 24 (1 to 6 cycles). MLN-273 ameliorated the oncocytic morphology in <italic>thyr</italic>-IFN&#x003b3; transgenic mice (<xref ref-type="fig" rid="pone-0007857-g003">Figure 3B</xref>, open circles), starting at cumulative doses of 3.6 mg/Kg and reaching a maximum at 6.0 mg/Kg (<xref ref-type="fig" rid="pone-0007857-g003">Figure 3B</xref>). An example of improved morphology is shown in <xref ref-type="fig" rid="pone-0007857-g003">Figure 3C</xref>, which compares the thyroid appearance of a mouse receiving 6 mg (closed arrow in <xref ref-type="fig" rid="pone-0007857-g003">Figure 3B</xref>) to that of a mouse receiving 1.2 mg (open arrow in <xref ref-type="fig" rid="pone-0007857-g003">Figure 3B</xref>). No effect on thyroid morphology was seen in wild type mice receiving various doses of MLN-273 (<xref ref-type="fig" rid="pone-0007857-g003">Figure 3B</xref>, closed circles), or the mannitol control (<xref ref-type="fig" rid="pone-0007857-g003">Figure 3B</xref>, open circles at 0 mg/Kg). Serum T4 levels did not significantly improve upon MLN-273 treatment (data not shown).</p><fig id="pone-0007857-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0007857.g003</object-id><label>Figure 3</label><caption><title>Pharmacologic inhibition of proteasome using MLN-273.</title><p>(A) Schedule of MLN-273 administration. (B) The oncocytic phenotype typical of <italic>thyr</italic>-IFN&#x003b3; transgenic mice (open circles) improved upon MLN-273 administration in a dose-dependent fashion, beginning at cumulative doses of 3.6 mg/Kg of body weight. No morphological changes were observed in <italic>thyr</italic>-IFN&#x003b3; transgenic treated with mannitol control (open circles, dose 0), or in wild type littermates (closed circles). (C) Thyroid morphology at 40X and 100X of a <italic>thyr</italic>-IFN&#x003b3; transgenic mouse treated with 4.8 mg/Kg MLN-273 (closed arrow in <xref ref-type="fig" rid="pone-0007857-g002">Figure 2B</xref>), and another treated with 1.2 mg/Kg MLN-273. (D) Administration of 12 injections of 0.3 mg/Kg MLN-273 significantly improved the oncocytic phenotype of <italic>thyr</italic>-IFN&#x003b3; transgenic mice. (E) The improvement was also evident macroscopically by a decrease in goiter size.</p></caption><graphic xlink:href="pone.0007857.g003"/></fig><p>We repeated the experiment using a dose of 0.3 mg/Kg for 12 injections (cumulative dose of 3.6 mg/Kg) in 44 mice (28 wild type and 16 transgenic). The oncocytic phenotype improved in <italic>thyr</italic>-IFN&#x003b3; transgenic mice receiving MLN-273 compared to those receiving mannitol (<xref ref-type="fig" rid="pone-0007857-g003">Figure 3D</xref>, p&#x0200a;&#x0003d;&#x0200a;0.022). The improvement was also evident by an approximate 6-fold reduction in the weight of thyroid-tracheal blocks (<xref ref-type="fig" rid="pone-0007857-g003">Figure 3E</xref>).</p></sec><sec id="s2d"><title>Genetic Deletion of LMP2, but Not LMP7, Corrects the Oncocytic Phenotype</title><p>To assess genetically the effects of immunoproteasome blockade, we crossed <italic>thyr</italic>-IFN&#x003b3; transgenic mice to mice lacking either LMP2 or LMP7. <italic>Thyr</italic>-IFN&#x003b3; transgenic - LMP2 knockout mice showed a significantly improved thyroid morphology, with minimal architectural disruption (<xref ref-type="fig" rid="pone-0007857-g004">Figure 4A left panel, and 4B</xref>), and a limited number of oncocytes (<xref ref-type="fig" rid="pone-0007857-g004">Figure 4A</xref> middle panel, and 4C). Their thyrocytes resembled those of wild type littermates (<xref ref-type="fig" rid="pone-0007857-g004">Figure 4A</xref> middle panel). The phenotype was intermediate in <italic>thyr</italic>-IFN&#x003b3; transgenic mice having one copy of LMP2 (<xref ref-type="fig" rid="pone-0007857-g004">Figure 4A right panel</xref>). The scattered mononuclear infiltration typical of <italic>thyr</italic>-IFN&#x003b3; transgenic mice, instead, was not affected by the absence of LMP2, and lymphocytes could still be seen in the thyroid interstitium of <italic>thyr</italic>-IFN&#x003b3; transgenic-LMP2 knockout mice (<xref ref-type="fig" rid="pone-0007857-g004">Figure 4A</xref> middle panel). Overall, these results suggest that LMP2 is directly involved in the formation of oncocyte initiated by IFN&#x003b3;. During these studies we also noted that thyroid follicular cells from mice lacking only LMP2 were flatter than those observed in wild type controls (<xref ref-type="supplementary-material" rid="pone.0007857.s002">Figure S2A</xref>), suggesting an effect of LMP2 on thyroid hormonogenesis. In contrast to LMP2, lack of LMP7 did not improve the disrupted thyroidal morphology or the oncocytic phenotype seen in <italic>thyr</italic>-IFN&#x003b3; transgenic mice (<xref ref-type="supplementary-material" rid="pone.0007857.s002">Figure S2B</xref>).</p><fig id="pone-0007857-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0007857.g004</object-id><label>Figure 4</label><caption><title>Genetic deletion of LMP2 ameliorates thyroid morphology and function.</title><p>(A) Thyroid architecture of a <italic>thyr</italic>-IFN&#x003b3; transgenic-LMP2 knockout mouse at 40X (left panel) and 160X magnification (middle panel). Thyroid architecture of a <italic>thyr</italic>-IFN&#x003b3; transgenic-heterozygous mouse (right panel). (B) Disruption score of the thyroid gland architecture in the 6 genotypes. (C) Oncocytic score in the 6 genotypes. (D) Serum total T4 levels in the 6 genotypes: lack of LMP2 ameliorates the hypothyroidism typical of <italic>thyr</italic>-IFN&#x003b3; transgenics. (E) Body weight of male (left panel) and female (right panel) mice in the 6 genotypes: lack of LMP2 ameliorates growth retardation typical of <italic>thyr</italic>-IFN&#x003b3; transgenic mice.</p></caption><graphic xlink:href="pone.0007857.g004"/></fig></sec><sec id="s2e"><title>Genetic Deletion of LMP2 Corrects the Hypothyroidism and Growth Defect Induced by IFN&#x003b3;</title><p>We have previously reported that <italic>thyr</italic>-IFN&#x003b3; transgenic mice develop primary hypothyroidism (low T4, high TSH, and low iodine uptake) <xref ref-type="bibr" rid="pone.0007857-Caturegli2">&#x0005b;5&#x0005d;</xref>, goiter <xref ref-type="bibr" rid="pone.0007857-Kimura1">&#x0005b;6&#x0005d;</xref>, and growth defect <xref ref-type="bibr" rid="pone.0007857-Kimura1">&#x0005b;6&#x0005d;</xref>. When crossed to LMP2 deficient mice, the <italic>thyr</italic>-IFN&#x003b3; double mutant mice corrected the hypothyroidism (<xref ref-type="fig" rid="pone-0007857-g004">Figure 4D</xref>, sixth group) and restored a normal body weight in both males (<xref ref-type="fig" rid="pone-0007857-g004">Figure 4E left panel</xref>) and females (<xref ref-type="fig" rid="pone-0007857-g004">Figure 4E right panel</xref>). These ameliorations were intermediate in <italic>thyr</italic>-IFN&#x003b3; transgenics with a single copy of LMP2 (<xref ref-type="fig" rid="pone-0007857-g004">Figure 4A right panel, and 4B</xref> fifth group). The results indicate that LMP2 is involved not only in oncocyte formation but also in the development of hypothyroidism and growth defect initiated by IFN&#x003b3;. LMP2 deficiency by itself had no influence on circulating T4 levels (<xref ref-type="fig" rid="pone-0007857-g004">Figure 4D</xref>, third group) or growth (<xref ref-type="fig" rid="pone-0007857-g004">Figure 4E</xref>, third group).</p><p>Thyroid accumulation of radioactive iodine in <italic>thyr</italic>-IFN&#x003b3; transgenics and <italic>thyr</italic>-IFN&#x003b3; transgenic-LMP2 knockout mice (<xref ref-type="supplementary-material" rid="pone.0007857.s003">Figure S3</xref>, third and fourth group) was significantly lower than that of wild type controls (<xref ref-type="supplementary-material" rid="pone.0007857.s003">Figure S3</xref>, first group). Mice lacking only LMP2 (<xref ref-type="supplementary-material" rid="pone.0007857.s003">Figure S3</xref>, second group) also had a significantly lower radioiodine accumulation than wild type controls, in keeping with the flattened thyrocyte morphology previously described (<xref ref-type="supplementary-material" rid="pone.0007857.s002">Figure S2A</xref>). LMP2 thus emerges as an important regulator of thyroid structure and function, capable of modulating iodine accumulation independently of IFN&#x003b3;.</p></sec><sec id="s2f"><title>LMP2 Is Expressed in Human Thyroid Oncocytes (H&#x000fc;rthle Cells)</title><p>Given the key role of LMP2 in the induction of mouse oncocytes, we assessed whether LMP2 was also expressed in archival thyroid glands removed from patients with Hashimoto thyroiditis, Graves disease, H&#x000fc;rthle cell adenoma, or H&#x000fc;rthle cell carcinoma. LMP2 was expressed in all 19 Hashimoto thyroiditis specimens (<xref ref-type="table" rid="pone-0007857-t002">Table 2</xref>) with mention of H&#x000fc;rthle cells and in most of those (5 of 6) where H&#x000fc;rthle cells were not mentioned by the pathologist. LMP2 staining in Hashimoto thyroiditis was diffuse throughout the section (<xref ref-type="fig" rid="pone-0007857-g005">Figure 5, left panel</xref>) and of strong intensity (<xref ref-type="fig" rid="pone-0007857-g005">Figure 5, left panel</xref> inset), often useful to spot oncocytes in the midst of the diffuse mononuclear cell infiltration typical of this disease. LMP2 was also expressed in H&#x000fc;rthle cell adenomas (<xref ref-type="fig" rid="pone-0007857-g005">Figure 5</xref>, middle panel) and carcinoma (<xref ref-type="fig" rid="pone-0007857-g005">Figure 5, right panel</xref>), although levels varied greatly among patients and different areas of the same specimen (<xref ref-type="supplementary-material" rid="pone.0007857.s004">Figure S4A</xref>). LMP7 expression followed that of LMP2 in Hashimoto thyroiditis, H&#x000fc;rthle cell adenoma, and carcinoma (<xref ref-type="supplementary-material" rid="pone.0007857.s004">Figure S4B</xref>).</p><fig id="pone-0007857-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0007857.g005</object-id><label>Figure 5</label><caption><title>LMP2 expression in human thyroid.</title><p>LMP2 expression marks H&#x000fc;rthle cells in patients with Hashimoto thyroiditis (left panel) H&#x000fc;rthle cell adenoma (middle panel), or H&#x000fc;rthle cell carcinoma (right panel). The inset on the left panel shows that LMP2 is expressed specifically in H&#x000fc;rthle cells (oncocytes) surrounded by the lymphocytic infiltration.</p></caption><graphic xlink:href="pone.0007857.g005"/></fig><table-wrap id="pone-0007857-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0007857.t002</object-id><label>Table 2</label><caption><title>Distribution and intensity of LMP2 expression by immunohistochemistry in H&#x000fc;rthle cells present in Hashimoto thyroiditis, H&#x000fc;rthle cell adenoma, H&#x000fc;rthle cell carcinoma, and Graves disease.</title></caption><alternatives><graphic id="pone-0007857-t002-2" xlink:href="pone.0007857.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">strong LMP2 positive</td><td align="left" rowspan="1" colspan="1">mild LMP2 positive</td><td align="left" rowspan="1" colspan="1">no detectable LMP2</td><td align="left" rowspan="1" colspan="1">total</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Hashimoto thyroiditis with mention of H&#x000fc;rthle cells</td><td align="left" rowspan="1" colspan="1">18 (95&#x00025;)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">19</td></tr><tr><td align="left" rowspan="1" colspan="1">Hashimoto thyroiditis without mention of H&#x000fc;rthle cells</td><td align="left" rowspan="1" colspan="1">3 (50&#x00025;)</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">1<xref ref-type="table-fn" rid="nt102">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">6</td></tr><tr><td align="left" rowspan="1" colspan="1">H&#x000fc;rthle cell adenoma</td><td align="left" rowspan="1" colspan="1">5 (55&#x00025;)</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">9</td></tr><tr><td align="left" rowspan="1" colspan="1">H&#x000fc;rthle cell carcinoma</td><td align="left" rowspan="1" colspan="1">3 (43&#x00025;)</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">7</td></tr><tr><td align="left" rowspan="1" colspan="1">Graves disease</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">2</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label/><p>Autoimmune H&#x000fc;rthle cells strongly express LMP2.</p></fn><fn id="nt102"><label>&#x0002a;</label><p>This thyroid pathological specimen contained only infiltrating lymphocytes and no thyroid cells.</p></fn></table-wrap-foot></table-wrap><p>Overall the results suggest that oncocytes (H&#x000fc;rthle cells) arise in response to a chronic inflammatory milieu within the thyroid gland, forming a spectrum of morphological variants, with an &#x0201c;autoimmune H&#x000fc;rthle cell&#x0201d; at one end and a &#x0201c;neoplastic H&#x000fc;rthle cell&#x0201d; at the other end of the spectrum.</p></sec></sec><sec id="s3"><title>Discussion</title><p>The study reports that LMP2, an immunoproteasome subunit, is involved in the generation of oncocytes and hypothyroidism in a mouse model of Hashimoto thyroiditis, and that is also expressed in human oncocyte (H&#x000fc;rthle cell) lesions.</p><p>The role of LMP2 in the pathogenesis of autoimmune diseases has been explored by a limited number of studies with conflicting results. Some studies have positively linked LMP2 to autoimmunity. For example, polymorphisms in the LMP2 have been associated with autoimmune diseases like ankylosing spondylitis <xref ref-type="bibr" rid="pone.0007857-Maksymowych1">&#x0005b;10&#x0005d;</xref>, vitiligo <xref ref-type="bibr" rid="pone.0007857-Casp1">&#x0005b;11&#x0005d;</xref>, and psoriasis <xref ref-type="bibr" rid="pone.0007857-Kramer1">&#x0005b;12&#x0005d;</xref>. In addition, circulating levels of LMP2 <xref ref-type="bibr" rid="pone.0007857-Egerer1">&#x0005b;13&#x0005d;</xref> and antibodies to LMP2 <xref ref-type="bibr" rid="pone.0007857-Scheffler1">&#x0005b;14&#x0005d;</xref> are increased in patients with connective tissues disorders like systemic lupus erythematosus and Sj&#x000f6;gren syndrome <xref ref-type="bibr" rid="pone.0007857-Egerer2">&#x0005b;15&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007857-Krause1">&#x0005b;16&#x0005d;</xref>. On the other hand, one group has shown that the lack of splenic LMP2 is linked to development of type 1 diabetes in the NOD mouse <xref ref-type="bibr" rid="pone.0007857-Hayashi1">&#x0005b;17&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007857-Hayashi2">&#x0005b;18&#x0005d;</xref>, a report that has stimulated some controversy <xref ref-type="bibr" rid="pone.0007857-Kessler1">&#x0005b;19&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0007857-Runnels1">&#x0005b;20&#x0005d;</xref>. It is likely that the tissue levels of LMP2 change throughout the course of the autoimmune process in a tissue-specific manner. For example, Vives-Pi and colleagues, studying eight patients with Graves disease patients and four with type 1 diabetes, reported that thyroid glands expressed high but variable levels of LMP2 and LMP7, whereas pancreases had levels similar to those found in healthy controls <xref ref-type="bibr" rid="pone.0007857-VivesPi1">&#x0005b;21&#x0005d;</xref>. LMP2 increase did not always correspond to a similar LMP7 increase, in keeping with the notion that these two subunits are not always assembled together <xref ref-type="bibr" rid="pone.0007857-Griffin1">&#x0005b;22&#x0005d;</xref> in the immunoproteasome, contrary to the pairing of LMP2 and LMP10 <xref ref-type="bibr" rid="pone.0007857-Groettrup1">&#x0005b;23&#x0005d;</xref>. Our finding that only the lack of LMP2, but not LMP7, ameliorated diseases in <italic>thyr-</italic>IFN&#x003b3; transgenic mice supports these observations.</p><p>In addition to demonstrating at the molecular and tissue levels that LMP2 is a marker of oncocytes (H&#x000fc;rthle cells) in Hashimoto thyroiditis, this study also reports that LMP2 is increased in thyroid cancer. In patients with H&#x000fc;rthle cell adenomas or carcinomas the expression of LMP2 was clear, although more variable than that observed in Hashimoto thyroiditis. The variability could be due to fine gradations in the oncocytic phenotype: although oncocytes are defined by the combination of morphological features, these features form a continuous spectrum, leading us to hypothesize that the oncocyte emerging in Hashimoto thyroiditis (&#x0201c;autoimmune H&#x000fc;rthle cell) might be different from those found in cancer (&#x0201c;neoplastic H&#x000fc;rthle cell&#x0201d;). This hypothesis remains to be tested. Further studies are also needed to assess whether LMP2 levels correlate with clinical outcomes in patients with H&#x000fc;rthle cell carcinoma.</p><p>LMP2 was used in this study as a therapeutic target to control with MLN-273 the oncocytes present in transgenic mice over-expressing IFN&#x003b3; in the thyroid gland. MLN-273 (PS-273) is an emerging boronic acid proteasome inhibitor similar to Velcade (bortezomib or PS-341) <xref ref-type="bibr" rid="pone.0007857-Adams2">&#x0005b;24&#x0005d;</xref>, a drug used in the treatment of several cancers like multiple myeloma <xref ref-type="bibr" rid="pone.0007857-Richardson1">&#x0005b;25&#x0005d;</xref>, and more recently inflammatory <xref ref-type="bibr" rid="pone.0007857-Fissolo1">&#x0005b;26&#x0005d;</xref> and autoimmune <xref ref-type="bibr" rid="pone.0007857-Neubert1">&#x0005b;27&#x0005d;</xref> diseases. MLN-273, like Velcade, blocks the constitutive proteasome (&#x003b2;5 subunit) and the immunoproteasome <xref ref-type="bibr" rid="pone.0007857-Kuhn1">&#x0005b;28&#x0005d;</xref>. In vitro, MLN-273 effectively blocks the development of Plasmodium parasites <xref ref-type="bibr" rid="pone.0007857-Lindenthal1">&#x0005b;29&#x0005d;</xref> and Mycobacterium tuberculosis <xref ref-type="bibr" rid="pone.0007857-Hu1">&#x0005b;30&#x0005d;</xref>. In vivo, MLN-273 halts the degradation of dystrophin and dystrophin-associated proteins in a mouse model of Duchenne muscular dystrophy <xref ref-type="bibr" rid="pone.0007857-Bonuccelli1">&#x0005b;31&#x0005d;</xref>. It also improves the glomerular filtration rate in a pig model of hypercholesterolemia <xref ref-type="bibr" rid="pone.0007857-Chade1">&#x0005b;32&#x0005d;</xref>, although there is disagreement on whether targeting the proteasome actually worsens atherosclerosis <xref ref-type="bibr" rid="pone.0007857-Fukai1">&#x0005b;33&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0007857-Ludwig1">&#x0005b;35&#x0005d;</xref>. It remains to be tested whether proteasome inhibition is effective in the treatment of H&#x000fc;rthle cell carcinomas. As new inhibitors (like IPSI-001) are being developed that preferentially target the immunoproteasome rather than constitutive proteasome <xref ref-type="bibr" rid="pone.0007857-Kuhn1">&#x0005b;28&#x0005d;</xref>, it is possible that this treatment modality will extend to a larger number of autoimmune diseases. The treatment might be also applicable to oncocytic lesions found in other organs, like kidneys, salivary or adrenal glands.</p><p>Interestingly, the lack of LMP2 ameliorated the hypothyroidism seen in <italic>thyr-</italic>IFN&#x003b3; transgenic mice, providing a novel explanation for the pathogenesis of hypothyroidism typically found in patients with autoimmune thyroiditis. Architectural disruption of the thyroid gland by infiltrating lymphocytes and apoptosis of thyrocytes have traditionally been considered the cause of hypothyroidism in autoimmune thyroiditis, but they are not the target of therapeutic interventions, which instead rely on the administration of synthetic thyroxine. Although effective, this symptomatic treatment is unsatisfactory in a discrete percentage of hypothyroid patients, highlighting the need for new treatments based on disease pathogenesis. <italic>Thyr-</italic>IFN&#x003b3; transgenic mice can, therefore, provide a model to study chronic hypothyroidism, a feature not found in most animal models of autoimmune thyroiditis.</p><p>In summary, we report that thyroid oncocytes (H&#x000fc;rthle cells) arise in the thyroid gland in response to a chronic inflammatory milieu concomitant with LMP2 over expression, and suggest they form a spectrum of morphological variants with an &#x0201c;autoimmune H&#x000fc;rthle cell&#x0201d; at one end and a &#x0201c;neoplastic H&#x000fc;rthle cell&#x0201d; at the other end of the spectrum. Considering increasing reports of the association between Hashimoto thyroiditis and thyroid cancer <xref ref-type="bibr" rid="pone.0007857-Benvenga1">&#x0005b;36&#x0005d;</xref>, we strongly propose that LMP2 might be a potential therapeutic target for the protective treatment of oncocytic lesions and hypothyroidism as well.</p></sec><sec sec-type="materials|methods" id="s4"><title>Materials and Methods</title><sec id="s4a"><title>Mice</title><p>The study analyzed a total of 366 mice: 216 genetically modified, and 150 C57BL/6 wild type littermate controls. The genetically modified mice included the following genotypes, all on the BL/6 background: <italic>thyr</italic>-IFN&#x003b3; transgenics (N&#x0200a;&#x0003d;&#x0200a;95) (a model previously generated in our laboratory to express murine IFN&#x003b3; specifically in thyroid follicular cells <xref ref-type="bibr" rid="pone.0007857-Caturegli2">&#x0005b;5&#x0005d;</xref>), LMP2 knockout (N&#x0200a;&#x0003d;&#x0200a;29); LMP2 heterozygous (N&#x0200a;&#x0003d;&#x0200a;19); LMP2 knockout/IFN&#x003b3; transgenic (N&#x0200a;&#x0003d;&#x0200a;46); LMP2 heterozygous/IFN&#x003b3; transgenic (N&#x0200a;&#x0003d;&#x0200a;19); LMP7 knockout/IFN&#x003b3; transgenic (N&#x0200a;&#x0003d;&#x0200a;5); and STAT1 knockout/IFN&#x003b3; transgenic (N&#x0200a;&#x0003d;&#x0200a;3). The <italic>thyr</italic>-IFN&#x003b3; transgenic mice were generated as previously described. They express the murine IFN&#x003b3; gene under control of the rat thyroglobulin promoter, to support transcription specifically in thyroid follicular cells. LMP2 knockout mice and LMP7 knockout mice (C57BL/6 background) were kindly gifted from Dr. Whitton (The Scripps Research Institute, La Jolla, CA) <xref ref-type="bibr" rid="pone.0007857-Nussbaum1">&#x0005b;37&#x0005d;</xref>. The following primers were used for genotyping for LMP2 or LMP7 knockout mice, LMP2-2 primer<named-content content-type="gene">: CCCGTGTCCCTCCGAGATAC</named-content> and LMP2-4 primer<named-content content-type="gene">: GGGATCCAGGACCAGGAAAG</named-content> to detect endogenous <italic>Psmb9</italic> (LMP2) gene, LMP7A primer<named-content content-type="gene">: TCTATGGTGGCATCACTATGTT</named-content> and LMP7B primer<named-content content-type="gene">: TGGTACACTGTGGGCGATTGAG</named-content> to detect endogenous <italic>Psmb8</italic> (LMP7) gene, NEO A primer<named-content content-type="gene">: CTTGGGTGGAGAGGCTATTC</named-content> and NEO B primer<named-content content-type="gene">: AGGTGAGATGACAGGAGATC</named-content> to detect mutant gene containing <italic>neo</italic> gene. STAT1 knockout mice, also on the C57BL/6 background, were kindly donated by Dr. David Levy (New York University Medical Center, New York, NY) <xref ref-type="bibr" rid="pone.0007857-Durbin1">&#x0005b;38&#x0005d;</xref>. The following primers were used for genotyping for LMP2 or LMP7 knockout mice, Stat P1 primer<named-content content-type="gene">: GAGATAATTCACAAAATCAGAGAG</named-content> and Stat P2 primer<named-content content-type="gene">: CTGATCCAGGCAGGCGTTG</named-content> to detect endogenous <italic>Stat1</italic> gene, Stat P1 primer and Stat P3 primer<named-content content-type="gene">: TAATGTTTCATAGTTGGATATCAT</named-content> to detect mutant gene. All mice were bred in specific pathogen-free facilities at Johns Hopkins University following protocols conformed to the JHU Animal Care and Use Committee guidelines. For some experiments, mice were weighed at five-week old.</p></sec><sec id="s4b"><title>Human Thyroid Glands</title><p>Thyroid samples (N&#x0200a;&#x0003d;&#x0200a;43) for morphological and immunohistochemical studies were obtained from the archival surgical pathology specimens maintained in The Johns Hopkins Pathology Department, using a protocol approved by the Institutional Review Board. Samples included patients with Hashimoto thyroiditis (N&#x0200a;&#x0003d;&#x0200a;25), Graves disease (N&#x0200a;&#x0003d;&#x0200a;2), H&#x000fc;rthle cell adenoma (N&#x0200a;&#x0003d;&#x0200a;9), and H&#x000fc;rthle cell carcinoma (N&#x0200a;&#x0003d;&#x0200a;7).</p></sec><sec id="s4c"><title>Histopathology of Thyroid</title><p>After euthanasia, mouse tracheas with attached thyroids were removed and fixed for 48 hours in the zinc-based Beckstead's solution or buffer-saturated formalin. The specimen was then processed and embedded in paraffin. Six to 8 non sequential sections (5 &#x000b5;m thick) were cut from the tissue block and stained with hematoxylin and eosin (H&#x00026;E). The same tissue block used for H&#x00026;E histopathology was used to cut sections for immunohistochemistry.</p></sec><sec id="s4d"><title>TUNEL Staining to Detect Apoptosis in Mouse Thyroid Glands</title><p>Formalin-fixed thyroid sections were deparaffinized in xylene, rehydrated in decreasing concentrations of ethanol, and washed in phosphate buffer saline (PBS). Sections were then incubated at room temperature in proteinase K (20 &#x000b5;g/ml for 15 min), washed in distilled water, and then incubated in hydrogen peroxide (0.3&#x00025; for 10 min). TUNEL staining was performed using the ApopTag kit (Chemicon, Temecula, CA). Sections were first equilibrated in the kit buffer and then incubated for 1 hour at 37&#x000b0;C in a humidified chamber with terminal deoxynucleotidyl transferase conjugated to digoxigenin. Sections were then placed in a Coplin jar containing working strength stop/wash buffer, agitated for 15 seconds, and incubated for 10 min at RT. After washing in PBS, an anti-digoxigenin antibody conjugated to peroxidase was applied for 30 min at RT. After washing, apoptosis-specific color was obtained using diaminobenzidine, and overall morphology using Eosin Y Alcoholic (Richard-Allan Scientific, Kalamazoo, MI).</p></sec><sec id="s4e"><title>Electron Microscopy of Mouse Thyroid Glands</title><p>Thyroid glands were fixed for 1 hour at room temperature in 0.1 M cacodylate buffer pH 7.2, supplemented with 3 mM CaCl<sub>2</sub>, 2&#x00025; glutaraldehyde, and 4&#x00025; paraformaldehyde. Glands were then post-fixed for 1 hour at 4&#x000b0;C in cacodylate buffer supplemented with 3 mM CaCl<sub>2</sub> and 2&#x00025; osmium tetroxide. Glands were then washed for 30 min in 2&#x00025; uranyl acetate, and dehydrated first with increasing concentrations of ethanol (50&#x00025;, 70&#x00025;, 90&#x00025; and 100&#x00025;) and then with propylene oxide. Glands were then infiltrated with a propylene oxide-Epon mixture and embedded flat in Epon. Ultra-thin sections were cut and analyzed for electron microscopy using a Phillips CM12 (S)TEM microscope.</p></sec><sec id="s4f"><title>Long SAGE (Serial Analysis of Gene Expression) of CD45 Negative Mouse Thyrocytes</title><p>Thyroid lobes were collected from 3 <italic>thyr</italic>-IFN&#x003b3; transgenic female mice, and 16 wild type female littermates. Lobes were incubated immediately after dissection for 26 hours at 4&#x000b0;C in Eagle's minimal essential medium, supplemented with 1.2 U/mL dispase II (Roche Applied Science, Indianapolis, IN) and 0.25 U/mL collagenase II (Sigma, St. Louis, MO), to ensure a thorough diffusion of the enzymes into the tissue. Lobes were then digested for 20 min at 37&#x000b0;C in a shaking water bath, and then briefly in cold PBS containing 2 mM EDTA and 1&#x00025; bovine serum albumin to stop the digestion. After one wash, thyroid cells were first passed through 70 &#x000b5;M mesh filter, to remove large tissue debris, and then incubated for 15 minutes at 4&#x000b0;C with anti-CD45 paramagnetic microbeads (Miltenyi Biotech, Auburn, CA). After one wash, the mixture was applied to a MS column (Miltenyi Biotech) in a magnetic separator: the CD45 negative fraction (composed mainly of thyrocytes, parathyroid cells, and endothelial cells) was eluted by the addition of phosphate-buffered saline, supplemented with 2 mM EDTA and 0.5&#x00025; bovine serum albumin. The magnetic separation was repeated once. CD45 negative thyroid cells were counted with trypan blue and used to extract mRNA and perform Long SAGE as described by Saha S <italic>et al</italic>. <xref ref-type="bibr" rid="pone.0007857-Saha1">&#x0005b;39&#x0005d;</xref>. The SAGE sequencing data are available from the Gene Expression Omnibus repository of the National Center for Biotechnology Information (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geo">http://www.ncbi.nlm.nih.gov/geo</ext-link>), using series record number GSE15114.</p></sec><sec id="s4g"><title>Expression of Immunoproteasome Subunit mRNA in Mouse Thyroids by Semi-Quantitative Reverse Transcriptase PCR</title><p>Thyroid lobes from 1-month-old <italic>thyr</italic>-IFN&#x003b3; transgenics (N&#x0200a;&#x0003d;&#x0200a;3) and wild type littermates (N&#x0200a;&#x0003d;&#x0200a;3) were mechanically homogenized to extract mRNA using oligo (dT)25 magnetic beads (Invitrogen, Carlsbad, CA). Following DNase I (Invitrogen) treatment, mRNA was reverse transcribed into cDNA using Superscript II RNase H<sup>-</sup> reverse transcriptase (Invitrogen). The five mouse immunoproteasome subunits using the following specific primers: PA28&#x003b1; forward primer <named-content content-type="gene">5&#x02032;-CAAGCCAAGGTGGATGTGTTCC-3&#x02032;</named-content> and reverse primer<named-content content-type="gene"> 5&#x02032;-GATCATTCCCTTGGTTTCTCCACG-3&#x02032;</named-content>, PA28&#x003b2; forward primer <named-content content-type="gene">5&#x02032;-GCAGGAGAAGGAAGTCCCTA-3&#x02032;</named-content> and reverse primer <named-content content-type="gene">5&#x02032;-GATGGCTTTTCTTCACCCTTCGG-3&#x02032;</named-content>, LMP2 forward primer <named-content content-type="gene">5&#x02032;-ATGCTGCGGGCAGGAGCACCTACCG-3&#x02032;</named-content> and reverse primer <named-content content-type="gene">5&#x02032;-TCACTCATCGTAGAATTTTGGCAGCT-3&#x02032;</named-content>, LMP7 forward primer <named-content content-type="gene">5&#x02032;-ATGGCGTTACTGGATCTGTGCGGTGC-3&#x02032;</named-content> and reverse primer <named-content content-type="gene">5&#x02032;-TCACAGAGCGGCCTCTCCGTACTTGT-3&#x02032;</named-content>, LMP10 forward primer <named-content content-type="gene">5&#x02032;-AGGAATGCGTCCTTGGAACACG-3&#x02032;</named-content> and reverse primer <named-content content-type="gene">5&#x02032;-TCAATGCTCTCTGCAGCTTGGC-3&#x02032;</named-content>. Mouse G3PDH was amplified as quantitation control using forward primer <named-content content-type="gene">5&#x02032;-GCATCTTGGGCTACACTGAG-3&#x02032;</named-content> and the reverse primer <named-content content-type="gene">5&#x02032;-TCTCTTGCTCAGTGTCCTTG-3&#x02032;</named-content>. The cDNA from each proteasome sample was sequentially diluted and then amplified for GAPDH. The dilutions that gave similar GAPDH intensities were used for amplification of the proteasome subunits.</p></sec><sec id="s4h"><title>Expression of Immunoproteasome Subunit Proteins in Mouse and Human Thyroids by Immunohistochemistry</title><p>Sections were deparaffinized with xylene, rehydrated with decreasing concentrations of ethyl alcohol and finally PBS. Formalin-fixed sections (human section) were, then, treated with target retrieval solution (DAKO, Carpinteria, CA) for 10 min in steamer; no target retrieval treatment for zinc-based Beckstead's solution-fixed mouse tissues. After cool down and washing with PBS, endogenous peroxidase was blocked by treating the sections with 3&#x00025; H<sub>2</sub>O<sub>2</sub> in PBS for 30 min at room temperature. After blocking aspecific binding with 5&#x00025; normal goat serum, sections were incubated with the primary antibody; rabbit anti proteasome subunit (LMP2, LMP7, LMP10, PA28&#x003b1;, and PA28&#x003b2;; Biomol International, L.P., Plymouth Meeting, PA), in PBS supplemented with 1&#x00025; bovine serum albumin, and incubated overnight at 4&#x000b0;C in a humid chamber. Primary antibody was diluted for human thyroid sections as following; LMP2 (1&#x02236;200), LMP7 (1&#x02236;2,000), LMP10 (1&#x02236;1,000), PA28&#x003b1; (1&#x02236;4,000), PA28&#x003b2; (1&#x02236;20,000). Primary antibody was diluted for mouse sections as following; LMP2 (1&#x02236;400), LMP7 (1&#x02236;10,000), LMP10 (1&#x02236;4,000), PA28&#x003b1; (1&#x02236;12,000), PA28&#x003b2; (1&#x02236;40,000).</p><p>After washing, the biotin-conjugated secondary antibody (affinity purified goat anti-rabbit IgG, from DAKO, diluted 1&#x02236;1000 in PBS-1&#x00025;BSA) was incubated for 1 hr at room temperature. After rinsing, peroxidase-conjugated streptavidin (DAKO) was diluted 1&#x02236;500 in PBS and incubated for 30 min at RT. Finally, sections were incubated for 5 min with NovaRED substrate or DAB substrate (both from Vector Laboratories, Burlingame, CA) for color development and then rinsed in distilled water. Sections were counter-stained with hematoxylin (Vector Laboratories).</p></sec><sec id="s4i"><title>Proteasome Inhibitor Administration</title><p>To block pharmacologically the function of the proteasome, <italic>thyr</italic>-IFN&#x003b3; transgenic mice and wild type littermates were injected i.p with MLN-273. This compound, a gift from Millennium Pharmaceutical Inc. (Cambridge, MA), blocks like Velcade (Bortezomib) the constitutive proteasome (&#x003b2;5 subunit) and the immunoproteasome <xref ref-type="bibr" rid="pone.0007857-Kuhn1">&#x0005b;28&#x0005d;</xref>. MLN-273 was formulated as 1 part (8.3&#x00025;) active compound and 11 parts (91.7&#x00025;) mannitol vehicle. Mice received MLN-273 or mannitol control twice a week for 2 weeks, then rested for a week, and then were injected again until reaching cumulative formulated doses of 1.2, 2.0, 2.5, 3.6, 4.8, and 6.0 mg/Kg (<xref ref-type="fig" rid="pone-0007857-g003">Figure 3A</xref>).</p></sec><sec id="s4j"><title>Assessment of Thyroid Function by Serum Total T4 Levels</title><p>Serum total thyroxine (T4) was determined by a competitive RIA (Diasorin, Stillwater, MN), according to the manufacturer's instructions. Briefly, ten &#x000b5;l of serum were added to plastic tubes coated with a monoclonal antibody directed against T4. Then, 1 ml of tracer buffer containing <sup>125</sup>I-T4 was added to the tubes and the solution incubated at room temperature for 45 min. Tubes were then decanted and counted for 1 min in a gamma counter (Isodata-520, from Titertek, Huntsville, AL). Total T<sub>4</sub> concentrations were extrapolated from a standard curve generated using six T<sub>4</sub> standards ranging from 0 to 20 &#x000b5;g/dL.</p></sec><sec id="s4k"><title>Radioactive Iodine Uptake (RAIU)</title><p>Iodine uptake was determined using radioactive iodine. Mice were fed with iodine-deficient diet (TD95007 from HARLAN TEKLAD, Indianapolis, IN) for 3 weeks. Mice were injected with 10 &#x000b5;Ci of <sup>125</sup>I (carrier-free, Amersham) intraperitoneally. Mice were sacrificed 4 hours after injection of radioactive iodine, and thyroid lobes and muscle (negative control) were excised, weighed and counted using a gamma counter. Iodine uptake was normalized dividing the count by the weight of each tissue.</p></sec><sec id="s4l"><title>Detection of Thyroidal Gene Expression by Northern Hybridization</title><p>After thyroid lobes were excised and homogenated in TRIZOL (Invitrogen, Carlsbad, CA), total RNA was extracted following manufacture protocol. 10 &#x000b5;g of total RNA was separated by 1&#x00025; agarose gel electrophoresis and analyzed by Northern blot for the expression of LMP2. The signal from G3PDH was also obtained to adjust for the amount of RNA loaded in each lane; G3PDH probe was synthesized using pTRI-GAPDH-Mouse (Ambion, Austin, TX). Probe signals were quantified using the BAS-1500 Bioimaging Analyzer (Fuji Photo Film Co., Japan).</p></sec><sec id="s4m"><title>Statistical Analysis</title><p>Differences among the six genotypes were assessed using the non-parametric Kruskal-Wallis test, followed by Wilcoxon sing-rank test for the pairwise comparisons. All analyses were performed using Stata statistical software, release 10 (from Stata Corp., College Station, TX).</p></sec></sec><sec sec-type="supplementary-material" id="s5"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0007857.s001"><label>Figure S1</label><caption><p>(A) LMP2 and LMP10 protein expression by immunohistochemistry in <italic>thyr</italic>-IFN&#x003b3; transgenic-STAT1 knockout mice: lack of STAT1 abolishes the expression of both immunoproteasome subunits, as compared to that found in <italic>thyr</italic>-IFN&#x003b3; transgenic-STAT1 wild type controls (insets). (B) LMP2 RNA expression by Northern blotting in Fisher rat thyroid follicular cells (FRTL-5 line) stimulated with IFN&#x003b3;. Total RNA was extracted from FRTL-5 cells after 0, 3, 12, 24, 48 or 72 hours of IFN&#x003b3; stimulation, and hybridized with a rat LMP2 cDNA probe by mRNA expression was assessed by Northern hybridization. IFN&#x003b3; strongly induced LMP2 expression, beginning at 12 hours post-stimulation and plateauing at 48 hours. No oncocytic changes were seen morphologically in the thyroid cells during these culture time points.</p><p>(1.75 MB TIF)</p></caption><media xlink:href="pone.0007857.s001.tif" mimetype="image" mime-subtype="tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0007857.s002"><label>Figure S2</label><caption><p>(A) Thyroidal morphology of mice lacking just LMP2: the thyroid architecture is preserved (left panel), but thyrocytes are flatter (right panel) than wild type thyrocytes (right panel, inset). (B) Thyroid morphology of <italic>thyr</italic>-IFN&#x003b3; transgenic mice lacking LMP7: the absence of LMP7 has no effect on the oncocytic phenotype induced by IFN&#x003b3;.</p><p>(9.59 MB TIF)</p></caption><media xlink:href="pone.0007857.s002.tif" mimetype="image" mime-subtype="tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0007857.s003"><label>Figure S3</label><caption><p>Radioactive iodine accumulation in thyroid. The radioactive iodine accumulation is decreased in mice lacking LMP2, in <italic>thyr</italic>-IFN&#x003b3; transgenic mice, and in <italic>thyr</italic>-IFN&#x003b3; transgenic mice lacking LMP2. No significant difference was observed among LMP2 knockout, <italic>thyr</italic>-IFN&#x003b3; transgenics, and <italic>thyr</italic>-IFN&#x003b3; transgenic/LMP2 knockout mice.</p><p>(0.27 MB TIF)</p></caption><media xlink:href="pone.0007857.s003.tif" mimetype="image" mime-subtype="tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0007857.s004"><label>Figure S4</label><caption><p>Histological analysis of human H&#x000fc;rthle cells. (A) LMP2 expression varies in different areas of H&#x000fc;rthle cell adenomas: expression is lower (left panel, inset) in areas with more complex histopathology (left panel) than in areas with a more uniform appearance (right panel). (B) LMP7 expression in Hashimoto thyroiditis (left panel), H&#x000fc;rthle cell adenoma (middle panel), and H&#x000fc;rthle cell carcinoma (right panel).</p><p>(3.13 MB TIF)</p></caption><media xlink:href="pone.0007857.s004.tif" mimetype="image" mime-subtype="tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0007857.s005"><label>Table S1</label><caption><p>Top 10 genes expressed in <italic>thyr</italic>-IFN&#x003b3; transgenic mouse thyrocytes (total tag # is 43,718).</p><p>(0.06 MB DOC)</p></caption><media xlink:href="pone.0007857.s005.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0007857.s006"><label>Table S2</label><caption><p>Top 10 genes expressed only in <italic>thyr</italic>-IFN&#x003b3; transgenic mouse thyrocytes.</p><p>(0.04 MB DOC)</p></caption><media xlink:href="pone.0007857.s006.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0007857.s007"><label>Table S3</label><caption><p>Top 10 genes expressed in wild-type mouse thyrocytes (total tag # is 43,908).</p><p>(0.05 MB DOC)</p></caption><media xlink:href="pone.0007857.s007.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0007857.s008"><label>Table S4</label><caption><p>Top 10 genes expressed only in wild-type mouse thyrocytes.</p><p>(0.03 MB DOC)</p></caption><media xlink:href="pone.0007857.s008.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ref-list><title>References</title><ref id="pone.0007857-Cooper1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>GS</given-names></name><name><surname>Stroehla</surname><given-names>BC</given-names></name></person-group><year>2003</year><article-title>The epidemiology of autoimmune diseases.</article-title><source>Autoimmun Rev</source><volume>2</volume><fpage>119</fpage><lpage>125</lpage><pub-id pub-id-type="pmid">12848952</pub-id></mixed-citation></ref><ref id="pone.0007857-Caturegli1"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caturegli</surname><given-names>P</given-names></name><name><surname>Ruggere</surname><given-names>C</given-names></name></person-group><year>2005</year><article-title>Karl Hurthle! Now, who was he?</article-title><source>Thyroid</source><volume>15</volume><fpage>121</fpage><lpage>123</lpage><pub-id pub-id-type="pmid">15753669</pub-id></mixed-citation></ref><ref id="pone.0007857-Tallini1"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tallini</surname><given-names>G</given-names></name><name><surname>Carcangiu</surname><given-names>ML</given-names></name><name><surname>Rosai</surname><given-names>J</given-names></name></person-group><year>1992</year><article-title>Oncocytic neoplasms of the thyroid gland.</article-title><source>Acta Pathol Jpn</source><volume>42</volume><fpage>305</fpage><lpage>315</lpage><pub-id pub-id-type="pmid">1636432</pub-id></mixed-citation></ref><ref id="pone.0007857-Montone1"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montone</surname><given-names>KT</given-names></name><name><surname>Baloch</surname><given-names>ZW</given-names></name><name><surname>LiVolsi</surname><given-names>VA</given-names></name></person-group><year>2008</year><article-title>The thyroid Hurthle (oncocytic) cell and its associated pathologic conditions: a surgical pathology and cytopathology review.</article-title><source>Arch Pathol Lab Med</source><volume>132</volume><fpage>1241</fpage><lpage>1250</lpage><pub-id pub-id-type="pmid">18684023</pub-id></mixed-citation></ref><ref id="pone.0007857-Caturegli2"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caturegli</surname><given-names>P</given-names></name><name><surname>Hejazi</surname><given-names>M</given-names></name><name><surname>Suzuki</surname><given-names>K</given-names></name><name><surname>Dohan</surname><given-names>O</given-names></name><name><surname>Carrasco</surname><given-names>N</given-names></name><etal/></person-group><year>2000</year><article-title>Hypothyroidism in transgenic mice expressing IFN-gamma in the thyroid.</article-title><source>Proc Natl Acad Sci U S A</source><volume>97</volume><fpage>1719</fpage><lpage>1724</lpage><pub-id pub-id-type="pmid">10677524</pub-id></mixed-citation></ref><ref id="pone.0007857-Kimura1"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimura</surname><given-names>H</given-names></name><name><surname>Kimura</surname><given-names>M</given-names></name><name><surname>Westra</surname><given-names>WH</given-names></name><name><surname>Rose</surname><given-names>NR</given-names></name><name><surname>Caturegli</surname><given-names>P</given-names></name></person-group><year>2005</year><article-title>Increased thyroidal fat and goitrous hypothyroidism induced by interferon-gamma.</article-title><source>Int J Exp Pathol</source><volume>86</volume><fpage>97</fpage><lpage>106</lpage><pub-id pub-id-type="pmid">15810981</pub-id></mixed-citation></ref><ref id="pone.0007857-Tanaka1"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>K</given-names></name></person-group><year>2009</year><article-title>The proteasome: overview of structure and functions.</article-title><source>Proc Jpn Acad Ser B Phys Biol Sci</source><volume>85</volume><fpage>12</fpage><lpage>36</lpage></mixed-citation></ref><ref id="pone.0007857-Kloetzel1"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kloetzel</surname><given-names>PM</given-names></name></person-group><year>2004</year><article-title>Generation of major histocompatibility complex class I antigens: functional interplay between proteasomes and TPPII.</article-title><source>Nat Immunol</source><volume>5</volume><fpage>661</fpage><lpage>669</lpage><pub-id pub-id-type="pmid">15224091</pub-id></mixed-citation></ref><ref id="pone.0007857-Adams1"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>J</given-names></name><name><surname>Palombella</surname><given-names>VJ</given-names></name><name><surname>Sausville</surname><given-names>EA</given-names></name><name><surname>Johnson</surname><given-names>J</given-names></name><name><surname>Destree</surname><given-names>A</given-names></name><etal/></person-group><year>1999</year><article-title>Proteasome inhibitors: a novel class of potent and effective antitumor agents.</article-title><source>Cancer Res</source><volume>59</volume><fpage>2615</fpage><lpage>2622</lpage><pub-id pub-id-type="pmid">10363983</pub-id></mixed-citation></ref><ref id="pone.0007857-Maksymowych1"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maksymowych</surname><given-names>WP</given-names></name><name><surname>Tao</surname><given-names>S</given-names></name><name><surname>Vaile</surname><given-names>J</given-names></name><name><surname>Suarez-Almazor</surname><given-names>M</given-names></name><name><surname>Ramos-Remus</surname><given-names>C</given-names></name><etal/></person-group><year>2000</year><article-title>LMP2 polymorphism is associated with extraspinal disease in HLA-B27 negative Caucasian and Mexican Mestizo patients with ankylosing spondylitis.</article-title><source>J Rheumatol</source><volume>27</volume><fpage>183</fpage><lpage>189</lpage><pub-id pub-id-type="pmid">10648037</pub-id></mixed-citation></ref><ref id="pone.0007857-Casp1"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casp</surname><given-names>CB</given-names></name><name><surname>She</surname><given-names>JX</given-names></name><name><surname>McCormack</surname><given-names>WT</given-names></name></person-group><year>2003</year><article-title>Genes of the LMP/TAP cluster are associated with the human autoimmune disease vitiligo.</article-title><source>Genes Immun</source><volume>4</volume><fpage>492</fpage><lpage>499</lpage><pub-id pub-id-type="pmid">14551602</pub-id></mixed-citation></ref><ref id="pone.0007857-Kramer1"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kramer</surname><given-names>U</given-names></name><name><surname>Illig</surname><given-names>T</given-names></name><name><surname>Grune</surname><given-names>T</given-names></name><name><surname>Krutmann</surname><given-names>J</given-names></name><name><surname>Esser</surname><given-names>C</given-names></name></person-group><year>2007</year><article-title>Strong associations of psoriasis with antigen processing LMP and transport genes TAP differ by gender and phenotype.</article-title><source>Genes Immun</source><volume>8</volume><fpage>513</fpage><lpage>517</lpage><pub-id pub-id-type="pmid">17581627</pub-id></mixed-citation></ref><ref id="pone.0007857-Egerer1"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Egerer</surname><given-names>K</given-names></name><name><surname>Kuckelkorn</surname><given-names>U</given-names></name><name><surname>Rudolph</surname><given-names>PE</given-names></name><name><surname>Ruckert</surname><given-names>JC</given-names></name><name><surname>Dorner</surname><given-names>T</given-names></name><etal/></person-group><year>2002</year><article-title>Circulating proteasomes are markers of cell damage and immunologic activity in autoimmune diseases.</article-title><source>J Rheumatol</source><volume>29</volume><fpage>2045</fpage><lpage>2052</lpage><pub-id pub-id-type="pmid">12375310</pub-id></mixed-citation></ref><ref id="pone.0007857-Scheffler1"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheffler</surname><given-names>S</given-names></name><name><surname>Kuckelkorn</surname><given-names>U</given-names></name><name><surname>Egerer</surname><given-names>K</given-names></name><name><surname>Dorner</surname><given-names>T</given-names></name><name><surname>Reiter</surname><given-names>K</given-names></name><etal/></person-group><year>2008</year><article-title>Autoimmune reactivity against the 20S-proteasome includes immunosubunits LMP2 (beta1i), MECL1 (beta2i) and LMP7 (beta5i).</article-title><source>Rheumatology (Oxford)</source><volume>47</volume><fpage>622</fpage><lpage>626</lpage><pub-id pub-id-type="pmid">18375405</pub-id></mixed-citation></ref><ref id="pone.0007857-Egerer2"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Egerer</surname><given-names>T</given-names></name><name><surname>Martinez-Gamboa</surname><given-names>L</given-names></name><name><surname>Dankof</surname><given-names>A</given-names></name><name><surname>Stuhlmuller</surname><given-names>B</given-names></name><name><surname>Dorner</surname><given-names>T</given-names></name><etal/></person-group><year>2006</year><article-title>Tissue-specific up-regulation of the proteasome subunit beta5i (LMP7) in Sjogren's syndrome.</article-title><source>Arthritis Rheum</source><volume>54</volume><fpage>1501</fpage><lpage>1508</lpage><pub-id pub-id-type="pmid">16646031</pub-id></mixed-citation></ref><ref id="pone.0007857-Krause1"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krause</surname><given-names>S</given-names></name><name><surname>Kuckelkorn</surname><given-names>U</given-names></name><name><surname>Dorner</surname><given-names>T</given-names></name><name><surname>Burmester</surname><given-names>GR</given-names></name><name><surname>Feist</surname><given-names>E</given-names></name><etal/></person-group><year>2006</year><article-title>Immunoproteasome subunit LMP2 expression is deregulated in Sjogren's syndrome but not in other autoimmune disorders.</article-title><source>Ann Rheum Dis</source><volume>65</volume><fpage>1021</fpage><lpage>1027</lpage><pub-id pub-id-type="pmid">16414974</pub-id></mixed-citation></ref><ref id="pone.0007857-Hayashi1"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayashi</surname><given-names>T</given-names></name><name><surname>Faustman</surname><given-names>D</given-names></name></person-group><year>1999</year><article-title>NOD mice are defective in proteasome production and activation of NF-kappaB.</article-title><source>Mol Cell Biol</source><volume>19</volume><fpage>8646</fpage><lpage>8659</lpage><pub-id pub-id-type="pmid">10567588</pub-id></mixed-citation></ref><ref id="pone.0007857-Hayashi2"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayashi</surname><given-names>T</given-names></name><name><surname>Kodama</surname><given-names>S</given-names></name><name><surname>Faustman</surname><given-names>DL</given-names></name></person-group><year>2000</year><article-title>Reply to &#x02018;LMP2 expression and proteasome activity in NOD mice&#x02019;.</article-title><source>Nat Med</source><volume>6</volume><fpage>1065</fpage><lpage>1066</lpage><pub-id pub-id-type="pmid">11017113</pub-id></mixed-citation></ref><ref id="pone.0007857-Kessler1"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kessler</surname><given-names>BM</given-names></name><name><surname>Lennon-Dumenil</surname><given-names>AM</given-names></name><name><surname>Shinohara</surname><given-names>ML</given-names></name><name><surname>Lipes</surname><given-names>MA</given-names></name><name><surname>Ploegh</surname><given-names>HL</given-names></name></person-group><year>2000</year><article-title>LMP2 expression and proteasome activity in NOD mice.</article-title><source>Nat Med </source><volume>6</volume><fpage>1064; author reply 1065&#x02013;1066</fpage><pub-id pub-id-type="pmid">11017111</pub-id></mixed-citation></ref><ref id="pone.0007857-Runnels1"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Runnels</surname><given-names>HA</given-names></name><name><surname>Watkins</surname><given-names>WA</given-names></name><name><surname>Monaco</surname><given-names>JJ</given-names></name></person-group><year>2000</year><article-title>LMP2 expression and proteasome activity in NOD mice.</article-title><source>Nat Med</source><volume>6</volume><fpage>1064</fpage><lpage>1065; author reply 1065&#x02013;1066</lpage><pub-id pub-id-type="pmid">11017112</pub-id></mixed-citation></ref><ref id="pone.0007857-VivesPi1"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vives-Pi</surname><given-names>M</given-names></name><name><surname>Vargas</surname><given-names>F</given-names></name><name><surname>James</surname><given-names>RF</given-names></name><name><surname>Trowsdale</surname><given-names>J</given-names></name><name><surname>Costa</surname><given-names>M</given-names></name><etal/></person-group><year>1997</year><article-title>Proteasome subunits, low-molecular-mass polypeptides 2 and 7 are hyperexpressed by target cells in autoimmune thyroid disease but not in insulin-dependent diabetes mellitus: implications for autoimmunity.</article-title><source>Tissue Antigens</source><volume>50</volume><fpage>153</fpage><lpage>163</lpage><pub-id pub-id-type="pmid">9271825</pub-id></mixed-citation></ref><ref id="pone.0007857-Griffin1"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griffin</surname><given-names>TA</given-names></name><name><surname>Nandi</surname><given-names>D</given-names></name><name><surname>Cruz</surname><given-names>M</given-names></name><name><surname>Fehling</surname><given-names>HJ</given-names></name><name><surname>Kaer</surname><given-names>LV</given-names></name><etal/></person-group><year>1998</year><article-title>Immunoproteasome assembly: cooperative incorporation of interferon gamma (IFN-gamma)-inducible subunits.</article-title><source>J Exp Med</source><volume>187</volume><fpage>97</fpage><lpage>104</lpage><pub-id pub-id-type="pmid">9419215</pub-id></mixed-citation></ref><ref id="pone.0007857-Groettrup1"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Groettrup</surname><given-names>M</given-names></name><name><surname>Standera</surname><given-names>S</given-names></name><name><surname>Stohwasser</surname><given-names>R</given-names></name><name><surname>Kloetzel</surname><given-names>PM</given-names></name></person-group><year>1997</year><article-title>The subunits MECL-1 and LMP2 are mutually required for incorporation into the 20S proteasome.</article-title><source>Proc Natl Acad Sci U S A</source><volume>94</volume><fpage>8970</fpage><lpage>8975</lpage><pub-id pub-id-type="pmid">9256419</pub-id></mixed-citation></ref><ref id="pone.0007857-Adams2"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>J</given-names></name></person-group><year>2002</year><article-title>Development of the proteasome inhibitor PS-341.</article-title><source>Oncologist</source><volume>7</volume><fpage>9</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">11854543</pub-id></mixed-citation></ref><ref id="pone.0007857-Richardson1"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richardson</surname><given-names>PG</given-names></name><name><surname>Mitsiades</surname><given-names>C</given-names></name><name><surname>Hideshima</surname><given-names>T</given-names></name><name><surname>Anderson</surname><given-names>KC</given-names></name></person-group><year>2006</year><article-title>Bortezomib: proteasome inhibition as an effective anticancer therapy.</article-title><source>Annu Rev Med</source><volume>57</volume><fpage>33</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">16409135</pub-id></mixed-citation></ref><ref id="pone.0007857-Fissolo1"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fissolo</surname><given-names>N</given-names></name><name><surname>Kraus</surname><given-names>M</given-names></name><name><surname>Reich</surname><given-names>M</given-names></name><name><surname>Ayturan</surname><given-names>M</given-names></name><name><surname>Overkleeft</surname><given-names>H</given-names></name><etal/></person-group><year>2008</year><article-title>Dual inhibition of proteasomal and lysosomal proteolysis ameliorates autoimmune central nervous system inflammation.</article-title><source>Eur J Immunol</source><volume>38</volume><fpage>2401</fpage><lpage>2411</lpage><pub-id pub-id-type="pmid">18792018</pub-id></mixed-citation></ref><ref id="pone.0007857-Neubert1"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neubert</surname><given-names>K</given-names></name><name><surname>Meister</surname><given-names>S</given-names></name><name><surname>Moser</surname><given-names>K</given-names></name><name><surname>Weisel</surname><given-names>F</given-names></name><name><surname>Maseda</surname><given-names>D</given-names></name><etal/></person-group><year>2008</year><article-title>The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis.</article-title><source>Nat Med</source><volume>14</volume><fpage>748</fpage><lpage>755</lpage><pub-id pub-id-type="pmid">18542049</pub-id></mixed-citation></ref><ref id="pone.0007857-Kuhn1"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuhn</surname><given-names>DJ</given-names></name><name><surname>Hunsucker</surname><given-names>SA</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Voorhees</surname><given-names>PM</given-names></name><name><surname>Orlowski</surname><given-names>M</given-names></name><etal/></person-group><year>2009</year><article-title>Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors.</article-title><source>Blood</source><volume>113</volume><fpage>4667</fpage><lpage>4676</lpage><pub-id pub-id-type="pmid">19050304</pub-id></mixed-citation></ref><ref id="pone.0007857-Lindenthal1"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindenthal</surname><given-names>C</given-names></name><name><surname>Weich</surname><given-names>N</given-names></name><name><surname>Chia</surname><given-names>YS</given-names></name><name><surname>Heussler</surname><given-names>V</given-names></name><name><surname>Klinkert</surname><given-names>MQ</given-names></name></person-group><year>2005</year><article-title>The proteasome inhibitor MLN-273 blocks exoerythrocytic and erythrocytic development of Plasmodium parasites.</article-title><source>Parasitology</source><volume>131</volume><fpage>37</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">16038394</pub-id></mixed-citation></ref><ref id="pone.0007857-Hu1"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>G</given-names></name><name><surname>Lin</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Dick</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>RM</given-names></name><etal/></person-group><year>2006</year><article-title>Structure of the Mycobacterium tuberculosis proteasome and mechanism of inhibition by a peptidyl boronate.</article-title><source>Mol Microbiol</source><volume>59</volume><fpage>1417</fpage><lpage>1428</lpage><pub-id pub-id-type="pmid">16468986</pub-id></mixed-citation></ref><ref id="pone.0007857-Bonuccelli1"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonuccelli</surname><given-names>G</given-names></name><name><surname>Sotgia</surname><given-names>F</given-names></name><name><surname>Capozza</surname><given-names>F</given-names></name><name><surname>Gazzerro</surname><given-names>E</given-names></name><name><surname>Minetti</surname><given-names>C</given-names></name><etal/></person-group><year>2007</year><article-title>Localized treatment with a novel FDA-approved proteasome inhibitor blocks the degradation of dystrophin and dystrophin-associated proteins in mdx mice.</article-title><source>Cell Cycle</source><volume>6</volume><fpage>1242</fpage><lpage>1248</lpage><pub-id pub-id-type="pmid">17495527</pub-id></mixed-citation></ref><ref id="pone.0007857-Chade1"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chade</surname><given-names>AR</given-names></name><name><surname>Herrmann</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Krier</surname><given-names>JD</given-names></name><name><surname>Lerman</surname><given-names>A</given-names></name><etal/></person-group><year>2005</year><article-title>Effects of proteasome inhibition on the kidney in experimental hypercholesterolemia.</article-title><source>J Am Soc Nephrol</source><volume>16</volume><fpage>1005</fpage><lpage>1012</lpage><pub-id pub-id-type="pmid">15716331</pub-id></mixed-citation></ref><ref id="pone.0007857-Fukai1"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukai</surname><given-names>T</given-names></name></person-group><year>2007</year><article-title>Targeting proteasome worsens atherosclerosis.</article-title><source>Circ Res</source><volume>101</volume><fpage>859</fpage><lpage>861</lpage><pub-id pub-id-type="pmid">17967795</pub-id></mixed-citation></ref><ref id="pone.0007857-Herrmann1"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herrmann</surname><given-names>J</given-names></name><name><surname>Saguner</surname><given-names>AM</given-names></name><name><surname>Versari</surname><given-names>D</given-names></name><name><surname>Peterson</surname><given-names>TE</given-names></name><name><surname>Chade</surname><given-names>A</given-names></name><etal/></person-group><year>2007</year><article-title>Chronic proteasome inhibition contributes to coronary atherosclerosis.</article-title><source>Circ Res</source><volume>101</volume><fpage>865</fpage><lpage>874</lpage><pub-id pub-id-type="pmid">17823377</pub-id></mixed-citation></ref><ref id="pone.0007857-Ludwig1"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ludwig</surname><given-names>A</given-names></name><name><surname>Meiners</surname><given-names>S</given-names></name></person-group><year>2008</year><article-title>Targeting of the proteasome worsens atherosclerosis?</article-title><source>Circ Res</source><volume>102</volume><fpage>e37</fpage><pub-id pub-id-type="pmid">18276919</pub-id></mixed-citation></ref><ref id="pone.0007857-Benvenga1"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benvenga</surname><given-names>S</given-names></name></person-group><year>2008</year><article-title>Update on thyroid cancer.</article-title><source>Horm Metab Res</source><volume>40</volume><fpage>323</fpage><lpage>328</lpage><pub-id pub-id-type="pmid">18491251</pub-id></mixed-citation></ref><ref id="pone.0007857-Nussbaum1"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nussbaum</surname><given-names>AK</given-names></name><name><surname>Rodriguez-Carreno</surname><given-names>MP</given-names></name><name><surname>Benning</surname><given-names>N</given-names></name><name><surname>Botten</surname><given-names>J</given-names></name><name><surname>Whitton</surname><given-names>JL</given-names></name></person-group><year>2005</year><article-title>Immunoproteasome-deficient mice mount largely normal CD8&#x0002b; T cell responses to lymphocytic choriomeningitis virus infection and DNA vaccination.</article-title><source>J Immunol</source><volume>175</volume><fpage>1153</fpage><lpage>1160</lpage><pub-id pub-id-type="pmid">16002717</pub-id></mixed-citation></ref><ref id="pone.0007857-Durbin1"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durbin</surname><given-names>JE</given-names></name><name><surname>Hackenmiller</surname><given-names>R</given-names></name><name><surname>Simon</surname><given-names>MC</given-names></name><name><surname>Levy</surname><given-names>DE</given-names></name></person-group><year>1996</year><article-title>Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease.</article-title><source>Cell</source><volume>84</volume><fpage>443</fpage><lpage>450</lpage><pub-id pub-id-type="pmid">8608598</pub-id></mixed-citation></ref><ref id="pone.0007857-Saha1"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saha</surname><given-names>S</given-names></name><name><surname>Sparks</surname><given-names>AB</given-names></name><name><surname>Rago</surname><given-names>C</given-names></name><name><surname>Akmaev</surname><given-names>V</given-names></name><name><surname>Wang</surname><given-names>CJ</given-names></name><etal/></person-group><year>2002</year><article-title>Using the transcriptome to annotate the genome.</article-title><source>Nat Biotechnol</source><volume>20</volume><fpage>508</fpage><lpage>512</lpage><pub-id pub-id-type="pmid">11981567</pub-id></mixed-citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>This work was supported by National Institutes of Health (NIH) grants DK55670 and DK080334 to PC, and by an American Thyroid Association Grant (<ext-link ext-link-type="uri" xlink:href="http://www.thyroid.org/">http://www.thyroid.org/</ext-link>) to HJK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group></back></article>